Dengue virus vaccine compositions and methods of use thereof
View Patent ↗The present invention relates to dengue virus vaccine compositions comprising a first and a second dengue vaccine, wherein the first dengue vaccine is a live, attenuated dengue vaccine and the second dengue vaccine is a recombinant dengue subunit vaccine or an inactivated dengue vaccine; wherein the live attenuated dengue vaccine comprises at least one live, attenuated dengue virus or at least one live attenuated chimeric flavivirus. The dengue virus vaccine compositions of the invention may further comprise one or more adjuvants. In preferred embodiments of the invention, the first and the second dengue vaccine are tetravalent. The invention also relates to methods of using the dengue virus vaccine compositions of the invention to treat or prevent dengue infection, or to prevent, ameliorate, or delay the onset or progression of the clinical manifestations thereof.
1. A dengue virus immunogenic composition comprising a first and a second dengue composition and an adjuvant, wherein the first dengue composition is a tetravalent live, attenuated dengue immunogenic composition and the second dengue composition is a tetravalent non-replicating dengue immunogenic composition; wherein the live attenuated dengue immunogenic composition comprises at least one live, attenuated dengue virus or at least one live attenuated chimeric flavivirus, and wherein the tetravalent non-replicating dengue immunogenic composition comprises dengue E protein, or fragment thereof, from dengue virus type 1 (DEN1), dengue virus type 2 (DEN2), dengue virus type 3 (DEN3), and dengue virus type 4 (DEN4).
2. The composition of claim 1 , wherein the non-replicating dengue immunogenic composition is a recombinant dengue subunit immunogenic composition vaccine or an inactivated dengue immunogenic composition.
3. The composition of claim 1 , wherein the E proteins each constitute about 80% of the length of wild type E of DEN1, DEN2, DEN3 and DEN4, starting from amino acid residue 1 at its N-terminus.
4. The composition of claim 1 , wherein the adjuvant is an aluminum salt adjuvant.
5. The composition of claim 1 , wherein the amount of each E protein in the composition is from about 0.5 μg to about 500 μg.
6. The composition of claim 5 , wherein the amount of DEN4 E protein is about 1.5 to about 2.5 times the amount of DEN1, DEN2, and DEN3 E proteins.
7. The composition of claim 5 , wherein each E protein is recombinantly produced and expressed in insect host cells.
8. The composition of claim 1 , wherein the live attenuated dengue composition comprises four chimeric flaviviruses; wherein each chimeric flavivirus comprises the prM and E proteins of a single dengue virus serotype and the capsid and non-structural proteins of a different flavivirus, wherein each of the chimeric flaviviruses are attenuated.
9. The composition of claim 8 , wherein the capsid and nonstructural proteins of the four chimeric flaviviruses are from yellow fever virus.
10. The composition of claim 8 , wherein the capsid and nonstructural proteins of each of the four chimeric flaviviruses are from a different dengue serotype than the prM and E proteins.
11. The composition of claim 1 , wherein the potency of the live attenuated dengue immunogenic composition is from 10 to about 1×10 7 plaque forming units (PFU's).
12. The composition of claim 11 , wherein the potency of the live attenuated dengue vaccine is from about 1×10 3 to about 1×10 5 PFU's.
13. A method of inducing an immune response against dengue in a patient in need thereof, comprising administering to the patient an effective amount of a dengue virus immunogenic composition comprising a first and a second dengue composition and an adjuvant, wherein the first dengue composition is a tetravalent live, attenuated dengue immunogenic composition and the second dengue composition is a tetravalent non-replicating dengue immunogenic composition; wherein the live attenuated dengue immunogenic composition comprises at least one live, attenuated dengue virus or at least one live attenuated chimeric flavivirus and wherein the tetravalent non-replicating dengue immunogenic composition comprises dengue E protein, or fragment thereof, from dengue virus type 1 (DEN1), dengue virus type 2 (DEN2), dengue virus type 3 (DEN3), and dengue virus type 4 (DEN4).
14. A method of reducing the likelihood of dengue infection in a patient in need thereof, comprising administering to the patient an effective amount of a dengue virus immunogenic composition comprising a first and a second dengue composition and an adjuvant, wherein the first dengue composition is a tetravalent live, attenuated dengue immunogenic composition and the second dengue composition is a tetravalent non-replicating dengue immunogenic composition; wherein the live attenuated dengue immunogenic composition comprises at least one live, attenuated dengue virus or at least one live attenuated chimeric and wherein the tetravalent non-replicating dengue immunogenic composition comprises dengue E protein, or fragment thereof, from dengue virus type 1 (DEN1), dengue virus type 2 (DEN2), dengue virus type 3 (DEN3), and dengue virus type 4 (DEN4).
15. The method of claim 14 , further comprising (a) waiting a predetermined amount of time to pass after the dengue virus immunogenic composition is administered to the patient; and (b) administering to the patient the dengue virus immunogenic composition; whereby the likelihood of being infected with dengue is reduced in the patient.
16. The method of claim 15 , wherein the amount of time in step (a) is from 2 months to 2 years.
17. The composition of claim 1 , wherein the virus titer of the tetravalent live, attenuated dengue immunogenic composition is not impacted by the addition of the tetravalent non-replicating dengue immunogenic composition.
18. The composition of claim 1 , wherein the presence of the non-replicating dengue immunogenic composition does not impact the viability of the tetravalent live, attenuated dengue immunogenic composition.